Preliminary results from an ongoing phase II clinical trial of new lung cancer drug AXL1717 suggest that the drug effectively treats non-small cell lung cancer (NSCLC). In the study, patients with advanced NSCLC received either AXL1717 or chemotherapy with docetaxel (Taxotere) as a second-line treatment. AXL1717, which works by attacking a protein called IGF1R, appeared to be as effective as Taxotere at delaying cancer progression. AXL1717 may be a treatment option for patients who do not respond or become resistant to Taxotere or other second-line treatments. AXL1717 is manufactured by drug company Axelar. More information about the clinical trial can be found here: http://clinicaltrials.gov/show/NCT01561456
- IGF1R inhibitors
Bevacizumab (Avastin), which is approved for treatment of a number of advanced-stage cancer types, is commonly avoided in patients with brain metastases (cancer that has spread to the brain) because of fear of brain hemorrhages (bleeding in the brain). A retrospective study of 52 patients with advanced non-small cell lung cancer (NSCLC) who had received chemotherapy containing Avastin found no cases of serious bleeding events and no significant differences in survival or treatment side effects between patients with or without brain metastases. Avastin may therefore be a safe treatment option in NSCLC with brain metastases.
Research paper: https://www.jstage.jst.go.jp/article/acrt/20/2/20_47/_pdf
The roles of the genes IGF1R and EGFR in lung cancer were examined in patients with non-small cell lung cancer (NSCLC) who had their primary tumor surgically removed. Patients whose tumors had increased expression of both IGFR1R and EGFR were more likely to experience recurrence of the cancer after a shorter amount of time and had shorter survival times after surgery. This finding suggests that concurrent overexpression of IGF1R and EGFR is a negative prognosis factor in NSCLC and may indicate patients who are more likely to benefit from novel treatments with IGF1R inhibitors.